HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia Research/Science 10/28/2023
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
View this post in the Community →
Similar Community Posts Join
5 / 141 resultscommunity Hope Medicine HMI-115 Phase 1 Success in Australia! 14 hairs/cm2 increase in hair growth.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
community Hope Medicine has a new CEO. Calling it now, he's probably going to axe HMI.
Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.
community Any news about possible cures?
Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community what is a realistic timeline when does hmi-115 gets released? What are they doing in the non-clinical dev. phase?
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
Related Research
6 / 47 results
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
research The Pathophysiology of Polycystic Ovary Syndrome: Understanding PCOS and Its Endocrinology
The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.
research The State-of-the-Art in the Management of Androgenetic Alopecia: A Review of New Therapies and Treatment Algorithms
New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
research Efficacy of a Cosmetic Product Mimicking PRP in Androgenetic Alopecia
research An Open-Label Evaluator Blinded Study of the Efficacy and Safety of a New Nutritional Supplement in Androgenetic Alopecia: A Pilot Study
The supplement may help hair growth and is safe, but more research is needed.
research Topical Application of the Wnt/β-Catenin Activator Methyl Vanillate Increases Hair Count and Hair Mass Index in Women with Androgenetic Alopecia
Methyl vanillate spray increases hair count and hair mass in women with hair loss.